Table 4.
Per-cycle dosimetry estimates obtained with hybrid methods based on two time points for the first cycle and one time point or no imaging at all for subsequent cycles (induction cycles only, n = 173)
| Absorbed dose (Gy) | Correlation vs. 3TP (r)a | Relative error vs. 3TP (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3TP | 2TP/1TPD1 | 2TP/1TPD3 | 2TP/NI | 2TP/1TPD1 | 2TP/1TPD3 | 2TP/NI | 2TP/1TPD1 | 2TP/1TPD3 | 2TP/NI | |
| Kidney | 4.8 [2.9–6.6] (1.6–8.7) |
5.1 [3.0–7.1] (1.8–11.3) |
4.9 [3.0–6.9] (1.7–9.2) |
4.7 [2.7–7.3] (1.1–10.5) |
0.887 | 0.985 | 0.807 | 3.4 [− 9.5–26.8] (− 38.3–86.3) |
2.2 [− 2.0–7.4] (− 17.9–32.1) |
0.6 [− 23.5–27.8] (− 60.2–106.3) |
| Bone marrowself | 0.29 [0.14–0.65] (0.06–3.84) |
0.22 [0.11–0.73] (0.06–2.33) |
0.24 [0.13–0.64] (0.06–2.83) |
0.24 [0.10–0.65] (0.04–3.85) |
0.733 | 0.939 | 0.707 | −7.0 [− 56.6–76.3] (− 73.9–155.8) |
−7.2 [− 33.2–22.4] (− 44.2–51.0) |
−13.8 [− 56.0–65.3] (− 93.8–370.9) |
| Bone marrowcross | 0.023 [0.011–0.052] (0.005–0.100) |
0.022 [0.011–0.054] (0.003–0.113) |
0.021 [0.010–0.050] (0.004–0.107) |
0.022 [0.010–0.060] (0.003–0.141) |
0.966 | 0.991 | 0.907 | −2.2 [− 21.2–14.9] (− 55.1–66.4) |
−4.2 [− 15.7–2.7] (− 37.3–22.6) |
1.3 [− 35.7–40.8] (− 52.5–113.0) |
| Tumormaxb | 29.7 [6.2–65.9] (1.7–120.0) |
32.8 [7.0–66.6] (1.5–104.5) |
31.2 [6.2–66.8] (1.9–102.1) |
45.6 [9.9–113.9] (3.2–235.1) |
0.946 | 0.980 | 0.713 | 3.6 [− 20.4–39.0] (− 46.7–141.8) |
2.3 [− 11.5–21.6] (− 30.2–65.3) |
31.0 [− 13.0–192.5] (− 49.9–6171.7) |
D1 day 1, D3 day 3, NI no imaging, TP time point(s)
Data is presented as median [interdecile range] (range)
Median injected activity was 7.8 (range, 0.7–32.4) GBq
aSpearman’s correlation, P < 0.0001 in all cases
bn = 172